VK2735 for Obesity
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a phase 2, 13-week randomized, double-blind, placebo-controlled, parallel arm dose-finding study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of VK2735 Oral Formulation in adults who are obese (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition.VK2735 or matched placebo will be administered once daily.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot have used any GLP-1 receptor agonists or weight loss medications within 6 months before the screening.
Are You a Good Fit for This Trial?
This trial is for adults who are obese with a BMI of 30 or higher, or overweight with a BMI of at least 27 and have one weight-related health issue. Key eligibility details aren't provided, so interested individuals should inquire further about specific inclusion and exclusion criteria.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive VK2735 or placebo daily for weight management over 13 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- VK2735
Find a Clinic Near You
Who Is Running the Clinical Trial?
Viking Therapeutics, Inc.
Lead Sponsor